Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.35 USD
Change Today +0.015 / 4.55%
Volume 107.6K
RGDX On Other Exchanges
As of 11:05 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1640 Marengo Street

7th Floor

Los Angeles, CA 90033

United States

Phone: 323-224-3900

Fax: 323-224-3096

Response Genetics, Inc., a life sciences company, is engaged in the research and development of clinical diagnostic tests for cancer. The company sells its ResponseDX diagnostic tests and provides clinical trial testing services to pharmaceutical companies. The company’s proprietary technologies enable it to extract ribonucleic acid (RNA) and deoxyribonucleic acid from tumor specimens that are stored as formalin-fixed and paraffin-embedded (FFPE) specimens and thereby to analyze genetic information contained in these tissues. Its technologies also enable the company to use the FFPE patient biopsies for the development of diagnostic tests. Tests Launched During 2013, the company added four additional tests to its ResponseDX offering, such as HER2 mutation detection, KIT mutation detection, MET FISH (Fluorescence in Situ Hybridization), and UGT1A1 SNP. In addition, it expanded its suite of profiles to include ResponseDX: Thyroid. HER2 Mutation Detection: In 2013, the company launched testing for HER2 mutations in non-small cell lung cancer (NSCLC). Activating mutations within the tyrosine kinase domain of the HER2 gene exist within a subset of NSCLC patients, and recent clinical studies suggest that NSCLC patients carrying these mutations might benefit from HER2-targeting therapies, such as trastuzumab and afatinib. The company’s Sanger sequencing based HER2 mutation detection test could be performed for patients for whom the company has stored a residual nucleic acid sample. cKIT Mutation Detection: In 2013, the company also began offering cKIT mutation detection in its ResponseDX: Melanoma and ResponseDX: Gastric panels. The company’s cKIT assay is a Sanger sequencing based test aimed to identify cKIT mutations, which are to be a major oncogenic event in melanoma and gastrointestinal stromal tumors (GIST). Imatinib (Gleevec), an oral tyrosine kinase inhibitor initially developed for treatment of chronic myelogenous leukemia, has been shown to inhibit cKIT. Mutations in cKIT have been proven to be predictive of response to imatinib and other drugs for both GIST and melanoma. Sunitinib, another tyrosine kinase inhibitor that targets cKIT, is approved for use with imatinib-resistant GIST, among other tumor types. MET Gene Amplification (FISH): Amplification of MET is associated with poor patient prognosis in NSCLC, brain, breast, colorectal, gastric, and head and neck carcinomas, and associated with resistance to radiotherapy in NSCLC patients and with resistance to anti-EGFR therapies in both colorectal and lung carcinomas. In 2013, the company introduced a FISH test for MET gene amplification, which replaces its previous RNA expression assay for cMET. UGT1A1 Test: In 2013, the company added UGT1A1 testing to its ResponseDX: Colon panel. UGT1A1 is the primary enzyme for the clearance of the chemotherapy drug irinotecan, which is administered to metastatic colorectal cancer patients. Certain polymorphisms in the UGT1A1 gene are associated with increased potential for adverse clinical outcomes upon treatment with irinotecan, including neutropenia and elevated levels of diarrhea, and the U.S. Food and Drug Administration (FDA) provides guidelines on prescribing irinotecan based on UGT1A1 genotyping prior to therapy. The company added five additional tests to its ResponseDX offering, such as ROS1 FISH, ROS1 RT-PCR, c-MET, HER2 FISH, and VEGFR2. In addition, it made its NRAS assay available to its ResponseDX: Melanoma offering after publications showed that NRAS mutational status might be predictive for BRAF inhibitor response in metastatic melanoma patients. Technologies ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, and ResponseDX: Breast The company developed ResponseDX in part by using its technology to extract genetic information from FFPE tumor specimens. Its technology provides gene expression, mutation detection and gene amplification/rearrangement information for each patient’s tumor tissue specimen. ResponseDX: Lung comprises tests grouped into ‘Driver’, ‘Expanded Driver’, and ‘Academic’ profiles. The Driver profile includes EGFR


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGDX:US $0.35 USD +0.015

RGDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $10.90 USD +0.03
Psychemedics Corp $14.92 USD -0.63
Rosetta Genomics Ltd $3.58 USD -0.04
Signal Genetics Inc $1.66 USD -0.0599
Veracyte Inc $10.41 USD +0.37
View Industry Companies

Industry Analysis


Industry Average

Valuation RGDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESPONSE GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at